A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Status:
Completed
Trial end date:
2009-04-08
Target enrollment:
Participant gender:
Summary
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of
pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the
safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.